Hengrui Medicine (600276.SH): HRS-4729 Injection Receives Drug Clinical Trial Approval Notice

Zhitong Finance APP News, Hengrui Pharmaceuticals (600276.SH) announced that recently, the company and its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration regarding HRS-4729 injection, and will soon initiate clinical trials.